Skip to content

Author

Ya-Nan Song

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cost-effectiveness of durvalumab consolidation therapy in limited-stage small-cell lung cancer: A Chinese and U.S. payer perspective analysis.

BACKGROUND The ADRIATIC trial has established durvalumab as a new standard of care for limited-stage small-cell lung cancer (LS-SCLC) by showing significant survival benefits after chemoradiotherapy (CRT). In this study, the cost-effectiveness of this regimen was evaluated from Chinese and U.S. payer perspectives. ME...

Cheng-Jun Wang, Shi-Xian Liu, Chuang Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.